Overview

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an antidepressant.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Antidepressive Agents